The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant-Reference-Cited by-同舟云学术

The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant

Published:2019-09 Issue:5 Volume:23 Page:378-384
ISSN:1278-3218
Container-title:Cancer/Radiothérapie
language:en
Short-container-title:Cancer/Radiothérapie

Author:

Furlan C.,Matrone F.,Rupolo M.,Ciancia R.,Zanet E.,Montante B.,Palazzari E.,Navarria F.,Trovo M.,Bulian P.,Spina M.,Coassin E.,Mascarin M.,De Paoli A.,Franchin G.,Michieli M.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference24 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

3. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma;Rancea;Cochrane Database Systc Rev,2013

4. How I treat relapsed and refractory Hodgkin lymphoma;Kuruvilla;Blood,2011

5. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma;Sirohi;Ann Oncol,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience;Clinical Lymphoma Myeloma and Leukemia;2021-09

2. Favorable Outcome After Adjuvant Involved-Field Radiotherapy After Autologous Hematopoietic Stem-Cell Transplantation in Patients With High-Risk Relapsed/Refractory Lymphoma: A Single-Center Experience;Clinical Lymphoma Myeloma and Leukemia;2021-02

3. Risk stratification and prognostic biomarkers in relapsed Hodgkin lymphoma;British Journal of Haematology;2020-06-07